Navigation Links
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life

lly focused in gastroenterology and dermatology. It is currently marketing proprietary products for the treatment and management of ulcerative colitis, Crohn's disease, food intolerances and dermatological disorders. Giuliani's R&D pipeline includes new chemical entities and biotechnological products targeted to treat inflammatory and autoimmune diseases.

COSMO Pharmaceuticals SpA

Cosmo is a speciality pharma company that aims to become a global leader in optimized therapies for certain gastrointestinal diseases. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulcerative colitis and Crohn's disease, and colon infections. Cosmo's most advanced development product is LIALDA(TM)/ MEZAVANT(TM) a treatment for ulcerative colitis that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo's proprietary MMX technology is at the core of the company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. For further information on Cosmo, please visit the Company's website: http://www.cosmopharmaceuticals.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to th
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
3. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
4. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
5. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
6. New Survey Finds Troubling Data on American Asthma Sufferers
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinsons Disease
11. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
(Date:7/30/2015)... 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and webcast at 5:00 p.m. Eastern Time (2:00 p.m. ... second quarter 2015 financial results and provide a corporate ... NASDAQ Global Select Market closes that day. ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/30/2015)... , July 30, 2015 EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and other ... conference call on Thursday, August 6, 2015, at 11:00 ... second quarter ended June 30, 2015, and to provide ... Neurometabolic Therapy, delivered via the Maestro® System. ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3
... May 18 AccuVein LLC today announced it had signed ... sell the AV300 vein finder in India . With ... , , ... veins for blood draw , IV infusion and blood ...
... SAN FRANCISCO , May 18 Teva ... treated with a standard or low dose of ENJUVIA® (synthetic ... often they were awakened at night by hot flashes compared ... at the 58th Annual Clinical Meeting of the American College ...
Cached Medicine Technology:AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 2AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 2New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 4New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 5New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 6New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 7
(Date:7/30/2015)... ... ... Ross A. Clevens, MD, FACS has been reappointed by the University ... This is Dr. Clevens’ second appointment by the prestigious school. Over the past ... and a valuable mentoring program for medical students. , The University ...
(Date:7/30/2015)... Beach, California (PRWEB) , ... July 30, 2015 ... ... and services, announced today that the latest issue of Inclusive™ magazine, its multimedia ... digital platforms. The digital edition of the new issue, Volume 6, Issue 2, ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Partners All-Star at the annual All-Stars Summit. Google Partners is the platform for ... may receive the full support and tools necessary to run successful search marketing ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Quintessa Medical Spa ... is a nonsurgical treatment designed specifically for the elimination of excess tissue ... the first locations in the state of Wisconsin to offer this innovative treatment. , ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription ... Saturday, September 26, 2015 from 10:00 AM to 2:00 PM local time. On ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3
... NY (March 3, 2009) A study published in the ... (AJN) found that almost 40% of nurses who were on ... misconduct between 2001 and 2005. Nurses on probation who ... recidivate, suggesting that licensing boards should carefully screen and monitor ...
... this country. Many employers don,t want to hire them, and ... their own communities and families, the mentally ill are often ... efforts to combat the stigma of mental illness, but with ... are so powerful: Mental patients are either violently dangerous or ...
... March 3 /PRNewswire-USNewswire/ - - The following ... Action Network, American Heart Association, American Lung Association ... strongly support the bipartisan legislation introduced today to ... with effective authority to regulate tobacco products. ...
... undamaged areas to compensate, study finds , , TUESDAY, March ... to start losing his or her sight, the affected ... parts of the eye, Massachusetts Institute of Technology researchers ... the brain changes when its inputs change. Neurons seem ...
... 3 Tyco International Ltd. (NYSE: TYC ; ... a Special General Meeting of shareholders on March 12, 2009 ... The Annual General Meeting will begin at 9:00 a.m. ... Meeting at 9:30 a.m. Atlantic Time. During the meetings, ...
... Center is participating in a National Institutes of Health ... to reduce the risk of stroke patients suffering another ... stroke victims for high blood pressure and cholesterol, along ... in a patient,s brain, is better than intensive medical ...
Cached Medicine News:Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 2Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 3Health News:His and hers: Study examines the role of gender in the stigma of mental illness 2Health News:Congress Can Deliver Historic Victory for Children and America's Health By Granting FDA Authority Over Tobacco Products 2Health News:Congress Can Deliver Historic Victory for Children and America's Health By Granting FDA Authority Over Tobacco Products 3Health News:Brain Adapts to Age-Related Eye Disease 2Health News:Tyco to Host 2009 Annual General Meeting and Special General Meeting of Shareholders 2Health News:Preventing a second stroke is focus of study at Rush University Medical Center 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: